DDX53 and neoplasm: We found that the mice cured of primary challenged tumor by PTT dramatically reduced secondary tumor growth in the spleen compared to PBS- and LPS-treated primary challenged CT26 in the mice 15 days after secondary tumor injection (Figure 5A).